Cargando…

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

BACKGROUND: Daratumumab was the first monoclonal CD38 antibody with single-agent activity approved for the treatment of multiple myeloma. Moreover, daratumumab demonstrated high response rates in relapsed immunoglobulin light-chain (AL) amyloidosis. PATIENTS AND METHODS: In our single-center retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeryczynski, G., Antlanger, M., Duca, F., Binder-Rodriguez, C., Reiter, T., Simonitsch-Klupp, I., Bonderman, D., Kain, R., Krauth, M.-T., Agis, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937667/ https://www.ncbi.nlm.nih.gov/pubmed/33667762 http://dx.doi.org/10.1016/j.esmoop.2021.100065

Ejemplares similares

Role of Daratumumab in Cardiac AL Amyloidosis
por: Gertz, Morie A.
Publicado: (2022)

Teduglutide in amyloidosis‐associated intestinal failure
por: Luhn, Clara, et al.
Publicado: (2023)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis
por: Binder, Christina, et al.
Publicado: (2020)

Hemodynamic Profiles and Their Prognostic Relevance in Cardiac Amyloidosis
por: Duca, Franz, et al.
Publicado: (2020)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
por: Jeryczynski, Georg, et al.
Publicado: (2021)

Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy: Breaking a dangerous bond
por: Jeryczynski, Georg, et al.
Publicado: (2022)

Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response
por: Demyanets, Svitlana, et al.
Publicado: (2020)

Machine Learning Enables Prediction of Cardiac Amyloidosis by Routine Laboratory Parameters: A Proof-of-Concept Study
por: Agibetov, Asan, et al.
Publicado: (2020)

Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement
por: Bonderman, Diana, et al.
Publicado: (2020)

Convolutional Neural Networks for Fully Automated Diagnosis of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging
por: Agibetov, Asan, et al.
Publicado: (2021)

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
por: Schalling, Martin, et al.
Publicado: (2017)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021)

Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis
por: Sun, Chunyan, et al.
Publicado: (2022)

Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy
por: Chitimus, Diana Maria, et al.
Publicado: (2022)

News in AL Amyloidosis ASH 2016: A rapidly evolving field of investigation
por: Agis, Hermine
Publicado: (2017)

Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience
por: Roccatello, Dario, et al.
Publicado: (2020)

Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
por: Suzuki, Kenshi, et al.
Publicado: (2023)

Light‐chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome
por: Nitsche, Christian, et al.
Publicado: (2020)

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2016)

Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2017)

Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots
por: Auer-Grumbach, Michaela, et al.
Publicado: (2020)

Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab
por: Rybinski, Brad, et al.
Publicado: (2021)

Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping
por: Antlanger, Marlies, et al.
Publicado: (2018)

T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab‐based therapy
por: Wang, Yujia, et al.
Publicado: (2021)

Machine learning-derived electrocardiographic algorithm for the detection of cardiac amyloidosis
por: Schrutka, Lore, et al.
Publicado: (2022)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

A case of multiple myeloma with AL amyloidosis showing giant Russel bodies
por: Mcphaden, Heather, et al.
Publicado: (2023)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report
por: Li, Xian, et al.
Publicado: (2022)

AL Amyloidosis
por: Desport, Estelle, et al.
Publicado: (2012)

Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
por: Heinemann, Tim, et al.
Publicado: (2022)

First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Prolonged follow‐up on lenalidomide‐based treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)—Real‐world data from the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Biomarkers in AL Amyloidosis
por: Fotiou, Despina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5dtheb6ds4fon8g2g13lj6k4h6